Alivus Life Sciences Ltd vs Astal Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1046 as of 13 Apr 15:30 . The P/E Ratio of Alivus Life Sciences Ltd changed from 13.4 on March 2022 to 27.2 on March 2025 . This represents a CAGR of 19.36% over 4 yearsThe P/E Ratio of Astal Laboratories Ltd changed from 437.5 on March 2021 to 8.4 on March 2025 . This represents a CAGR of -54.64% over 5 years The Market Cap of Alivus Life Sciences Ltd changed from ₹ 5624 crore on March 2022 to ₹ 13229 crore on March 2025 . This represents a CAGR of 23.84% over 4 yearsThe Market Cap of Astal Laboratories Ltd changed from ₹ 3.47 crore on March 2021 to ₹ 74.72 crore on March 2025 . This represents a CAGR of 84.77% over 5 years The revenue of Alivus Life Sciences Ltd for the Dec '25 is ₹ 686.82 crore as compare to the Sep '25 revenue of ₹ 602.7 crore. This represent the growth of 13.96% The revenue of Astal Laboratories Ltd for the Dec '25 is ₹ 52.27 crore as compare to the Sep '25 revenue of ₹ 37.55 crore. This represent the growth of 39.2% The ebitda of Alivus Life Sciences Ltd for the Dec '25 is ₹ 219.54 crore as compare to the Sep '25 ebitda of ₹ 193.89 crore. This represent the growth of 13.23% The ebitda of Astal Laboratories Ltd for the Dec '25 is ₹ 3.59 crore as compare to the Sep '25 ebitda of ₹ 3.9 crore. This represent the decline of -7.95% The net profit of Alivus Life Sciences Ltd changed from ₹ 111.48 crore to ₹ 150.26 crore over 7 quarters. This represents a CAGR of 18.60% The net profit of Astal Laboratories Ltd changed from ₹ 1.69 crore to ₹ 2.36 crore over 7 quarters. This represents a CAGR of 21.02% The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 12.62 % on March 2025 . This represents a CAGR of -32.68% over 4 yearsThe Dividend Payout of Astal Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Alivus Life Sciences Ltd

Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Astal Laboratories Ltd

Astal Laboratories Limited was formerly incorporated as a public company limited by shares on August 03, 1993 in the name of Macro International Limited.
The Company was taken over under SEBI takeover guidelines in 2022 and the main objects of the Company was changed to 'Manufacture and Sales of Pharmaceutical Intermediates and Bulk Drugs'.
Subsequently the name of the Company was changed to Astal Laboratories Limited in May, 2024.
The Company is now a subsidiary of Aceso Research Labs LLP. The Company was promoted by the Kanpur based business house of Parasrampurias.
The Company set up a departmental store at Plaza Kalpana, Birhana Road, Kanpur, offering products such as readymade garments, electronic items, leather items, stationery, books, fast food centre etc. During 1996-97, the departmental store project succeeded, only Saree Division and Archies Card Division was in operation.

FAQs for the comparison of Alivus Life Sciences Ltd and Astal Laboratories Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Astal Laboratories Ltd?

Market cap of Alivus Life Sciences Ltd is 12,733 Cr while Market cap of Astal Laboratories Ltd is 262 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Astal Laboratories Ltd?

The stock performance of Alivus Life Sciences Ltd and Astal Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Astal Laboratories Ltd?

As of May 4, 2026, the Alivus Life Sciences Ltd stock price is INR ₹1037.5. On the other hand, Astal Laboratories Ltd stock price is INR ₹62.13.

How do dividend payouts of Alivus Life Sciences Ltd and Astal Laboratories Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Astal Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.